(Q79756908)
Statements
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement (English)
Menno V Huisman
Bengt I Eriksson
Ola E Dahl
Sylvia Haas
Ajay K Kakkar
Frank Misselwitz
Eva Muehlhofer
12 February 2007